Stifel maintains Amdocs at Buy, lowers price target to $46 from $71

What happened

Stifel maintained its Buy rating on Amdocs but cut its price target to $46 from $71, a 35.2% decrease. The new target implies 26.3% downside from Amdocs’ Nov. 3 closing price of $62.43.

Confirmed

Global impact / market context

The lower target signals that Stifel sees less potential value in Amdocs shares than before, even while keeping its Buy rating. If investors revise their expectations toward the new target, the shares could face selling pressure; the article gives no explanation for Stifel’s change.

Analyst inference

The update is an analyst opinion, not a reported change in Amdocs’ business or financial results. Its stated downside compares the target with the Nov. 3 close, so it is a reference point rather than a forecast of when or whether the share price will move.

Analyst inference

What to watch

1. Watch for Amdocs’ share price relative to Stifel’s $46 target; the article provides no later trading data to show how investors responded. Analyst inference
2. Look for further analyst rating or target changes, which could indicate whether other analysts share Stifel’s lower view of Amdocs’ potential value. Analyst inference
3. Check for company results or guidance that could clarify whether changes in revenue, costs, or cash available help explain the lower target. Analyst inference

Evidence

• Original source link unavailable